

INTERNATIONAL CANCER IMAGING SOCIETY
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
28TH FEBRUARY 2025

Charity number 1082082
Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
28TH FEBRUARY 2025

Contents	Page
Report of the Trustees	1-10
Independent Examiner's Report	11
Statement of Financial Activities	12
Balance Sheet	13
Notes to the Accounts	14-19

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2025.

The Board of Trustees is satisfied with the performance of the charity during the year, considers that the charity is able to continue its activities during the coming year and that the charity's assets are adequate to fulfil its obligations.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznick
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Dr. Evis Sala
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Lucidarme
Dr. Thierry Huisman
Prof. Pek Lan Khong
Prof. Giuseppe Petralia
Prof. Anju Sahdev
Dr Bachir Taouli (appointed 12 October 2024)
Dr Hersh Chandarana (appointed 12 October 2024)
Dr Celso Matos (appointed 12 October 2024)

The key management personnel are the trustees and General Manager. Maureen Watts and Anna Campbell have both served as General Manager at different times during the period.

Secretary and Registered Office Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Registered Charity No: 1082082

Company Registration No: 03908709

Bankers Barclays Bank plc
9 Portman Square
London
W1A 3AL

**Independent
Examiners** JCS Accountants Ltd
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors Weightmans LLP
100 Old Hall Street
Liverpool
L3 9QJ

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

- a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
- b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
- c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
- d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects are through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Achievements and Performance

The shift in delegate preference for online learning has continued. While both in-person and online educational activities have continued to be offered to maintain the Society's status worldwide, the balance has continued to shift more towards online delivery. During this period two ICIS Interactive Masterclasses were delivered in-person but due to several factors, no in-person Masterclasses are planned for the 2025-2026 period. Early plans are for one in-person Masterclass in late 2026.

Online delivery of the ICIS Interactive Masterclass series continues to be well-received with the ever-popular whole-body MRI course continuing to sell-out whenever it is run. Plans are well-advanced for courses in 2025/2026 to be run on whole-body MRI, renal/adrenal imaging, head and neck imaging and prostate imaging. The Collective Minds Radiology (CMRAD) platform continued to be utilised for delivery of the masterclass workshops with an ongoing contract in place.

The bi-monthly webinars were re-established in 2024 to attract wider interest and to promote the Society's educational activities globally. The webinars remained free to watch live with subsequent posting on Society's YouTube channel. These have gone from strength to strength with each webinar attracting around 100 registrants and achieving a wide reach on YouTube. The success of the webinars will continue to provide a platform for growing the Society's reach and are a useful tool to widen awareness of upcoming ICIS Interactive Masterclasses.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

The 2024 ICIS Annual Teaching Course was held in Singapore from 25–27 September 2024, marking a significant milestone as the Society's first annual conference in Asia. With the President for the 2024 course based in Singapore, the Trustees endorsed the proposal to expand the Society's global footprint through this regional venture. A formal collaboration agreement was established with the Singapore Radiological Society and the College of Radiologists Singapore, resulting in a joint event titled 'ICIS SGCR-WIRES 2024'. This partnership aimed to introduce ICIS to a broader audience and lay the groundwork for future collaborations across Asia.

The meeting, themed 'Illuminating Cancer Care: The evolving role of imaging and intervention in modern clinical practice', featured a multidisciplinary programme designed to deliver cutting-edge insights and updates to the international radiological, nuclear medicine, and allied health communities. The event was well received, with strong attendance and positive feedback from participants. The income from the meeting was shared between the organising bodies and generated a surplus for the Society of £27,000, further reinforcing the success of this inaugural Asian collaboration.

ICIS satellite meetings returned and a joint session with the Taiwanese Radiological Society during the 22nd Asian Oceanian Congress of Radiology (AOCR 2024) was held in March 2024 in Taiwan. A Society booth for ICIS was included in the AOCR exhibition, which enabled promotion of the 2024 annual conference in Singapore. Satellite activities are considered an important part of the Society's educational output to reach and teach colleagues around the globe; thus further potential partnerships with international contacts will continue to be explored.

Attendance at the Radiological Society of North America 2024 Annual Scientific Meeting (RSNA) in November 2024, with a complimentary Society booth was once again taken up after the decision not to attend in 2023. It once again proved to be a useful forum for increasing awareness of the society, promoting the 2025 annual teaching course and making connections with potential sponsors.

Improving international visibility of the Society and worldwide marketing of Society events has remained under constant review. Regular social media activity through a range of platforms ('X', LinkedIn, Instagram, Facebook, and YouTube) has disseminated information, supporting the monthly e-newsletter, mailings and advertising.

A new ICIS website has been built and will be updated regularly, providing current and accurate information with the aim of increasing membership, attendance at teaching courses and readership of 'Cancer Imaging', all with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

'Cancer Imaging' has continued to be published by BioMed Central as an online open access journal. The Impact Factor (IF) released in June 2024 dropped from 4.9 to 3.5 following a reorganisation of how journal impact factors were collated. Other journals also saw a similar drop. Despite this, the journal continues to be ranked within the first quartile in Radiology journals and second quartile in Oncology journals, producing a 5-year IF of 4.3. The number of articles accessed continued to increase throughout the year, continuing to surpass 1 million during 2024.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

Professor Rodney Hicks [Melbourne, Australia] and Professor Annick Van den Abbeele [Boston, USA] stood down as Joint Honorary Editors-in-Chief and were replaced by Professor Khaled Elsayes (Houston, USA). Dr Thorsten Persigehl [Cologne, Germany] continued as Deputy Editor and was joined by Katherine Krajewski (Boston, USA), Elaine Yuen Phin Lee (Hong Kong), Olivier Lucidarme (Paris, France). Section Editors and the Editorial Board worked with the pool of submission reviewers to maintain this important work in a timely manner, supporting the Editor-in-Chief and Deputy Editors to develop 'Cancer Imaging' further.

Society membership levels were closely monitored throughout the year, showing a slight decline compared to the previous year. This was attributed to the registration process for the 2024 Annual Teaching Course in Singapore, which, due to the joint nature of the event, was managed via an external platform rather than the ICIS website. As a result, the usual increase in membership associated with course registration was not realised. It is anticipated that this trend will reverse in 2025, when registrations will once again be processed directly through the ICIS website, reinstating the link between course participation and membership uptake.

While the increasing availability of free online educational resources presents some challenges in maintaining the perceived value of the Society's members-only archive, this has not significantly impacted overall engagement. Member retention remains an area of focus, and the Society continues to explore ways to enhance the value of membership through exclusive content, networking opportunities, and educational benefits.

At 28 February 2025, the number of Society members was 113 representing 35 countries worldwide; the number of Fellows was 86, representing 21 countries.

Structure, Governance and Management

The International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity, governed by its memorandum and articles of association.

The Society is governed by a Board of trustees that oversees the management of the activities which the charity runs. The charity trustees are also Directors of the Company limited by guarantee. Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow. Benefits of membership include reduced registration fees for Society teaching courses, access to the members' area of the website with its expanding repository of recorded lectures and scientific posters and a 20% discount on the article processing charge for accepted publications in *Cancer Imaging*.

During the period under review the Trustees convened online on two occasions, in March 2024 and September 2024, one week before the commencement of the annual teaching course. Day to day decisions and activities of the Society are delegated by the Trustees to the Executive Board.

The Trustees proposed revision of the articles of association to remove the automatic appointment of the journal's Editor-in-Chief as a Trustee. Voting by Fellows adopted this amendment in October 2024.

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in May, July and November 2024, and January 2025. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk.

The activity implemented by the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications is reviewed at each Executive Board meeting, ensuring a focus on opportunities to develop key elements of Society activity. Consideration is also given to the benefits of Society membership with the intention of retaining existing and attracting new members.

Compliance with the General Data Protection Regulations (GDPR) is maintained in line with the UK General Data Protection Regulation (UK GDPR 2018), tailored by the Data Protection Act 2018, and subject to monitoring by the Society registration with the Information Commissioner's Office.

Risks

Regular review of the risk register ensured continual monitoring of Society practices and activities to determine that anticipated benefit outweighed possible risk to the Society; maintaining income streams and promoting the Society worldwide remained a top priority. The replacement of the Society website and administration system continued to feature as an identified risk while the project got underway in June 2024 and continued throughout the year. The Society requires a viable, modern, robust structure from which to operate and expand, considering the financial implications or impact on Society reserves. The project proved challenging due to the complex nature of the requirements and variable levels of understanding of the developers. Issues have been addressed with the developers agreeing to shoulder some of the additional costs. The project will continue into the 2025-2026 period and will come in slightly over budget, but it is not expected to have a material impact on the Society's financial position.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

Continued global interest in online educational activity in a very competitive virtual environment remained a challenge and risk to the Society. The Society's reputation as a provider of high-quality education on oncological imaging must be maintained; publication of high-quality research articles and reviews in 'Cancer Imaging' has retained the journal's international standing in its field. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series.

The Executive Board continued to consider potential natural disasters, international instability and terrorism as part of planning for in-person Society teaching courses, including any risk posed by infectious diseases, to report to the Trustees. The city and venue for each annual teaching course, or any in-person event, is chosen carefully with a request to include a break clause in the venue contract to mitigate potential risks should plans have to be changed. Insurance is reviewed every year.

The financial implications to the Society of any future satellite meetings will be carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of 'Cancer Imaging' will be kept under regular review.

Reference and administrative details

The Secretariat comprises two part-time employees, supported by contractors, who together maintain full and proper administrative control of all Society activities. During the period under review, the long-standing General Manager made the decision to retire and a new General Manager was appointed in May 2024. A six-month handover period was agreed and implemented.

Engagement of personnel continued with two-yearly renewable contracts, allowing for appropriate review, including salaries. ICIS does not have a central office facility for personnel; thus, overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters.

The project to replace the Society's website and administration system got underway in June 2024 with an initial completion target of Autumn 2024. However, due to the complexity of the requirements and challenges in translating these into technical specifications, the project timeline has extended into the current period. Significant difficulties were encountered in extracting and migrating data from legacy systems, and the high level of customisation required for the chosen open-source platform added further delays. Some aspects of the work exceeded the capabilities of the original development team, necessitating the recruitment of additional coders with specialised expertise. While the final cost of the project will exceed the original budget, this has been contained as much as possible thanks to the goodwill of the development partner, who agreed to absorb some of the additional costs arising from their own team's limitations and errors. Despite the setbacks, the project remains a strategic priority and is progressing steadily toward completion.

The Secretariat remained committed to enhancing engagement within the international radiology community to raise the profile of the Society, to encourage registration for teaching courses, to deliver successful courses and secure income for the continued functioning of the Society.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

Financial Review

The Trustees and the Executive Board continued to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. Securing industry support for the Society and teaching activities in a less robust worldwide economic environment proved more challenging, whilst reduced income because of lower registration numbers created additional pressure on securing positive financial outcome.

The Society's corporate sponsorship package aims to secure financial commitment to the Society by industry leaders. The Executive Board recommended that three-year commitment should be sought for each new contract negotiated, with a view to facilitating robust financial planning and forecasting.

Siemens Healthineers, a machine manufacturing company, continued their support. Support from other companies continues to be explored as a second corporate sponsor would provide additional guaranteed income, to relieve some financial pressure.

Following the successful implementation of selling online access to content recorded at previous annual teaching courses, this was repeated and content of ICIS-SGCR-WIRES 2024 was made available for purchase as an online package with access until September 2025. Income generated offset the cost of providing this content, generated a small surplus and served as a marketing tool for other Society activity. Continued online delivery of the ICIS Interactive Masterclass series remained a valued source of income as preference was expressed by delegates for this format.

'Cancer Imaging' remained a notable element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets both provided a beneficial income stream for the Society.

The Article Processing Charge (APC) is subject to annual review by the publisher. The Society has the option to apply a surcharge to the APC, the proceeds of which would provide direct additional income for the Society from each article published; however, it is judicious to consider the potential impact of a surcharge limiting the journal's attractiveness to authors, thereby reducing the number of submissions.

The Trustees had approved a budgeted deficit of £125,000 for the 2025 financial year, recognising the anticipated costs associated with the website redevelopment project and the strategic decision to hold the Annual Teaching Course in Asia for the first time, and as part of a joint meeting. This investment was considered a calculated risk to support the Society's long-term goal of expanding its reach and influence in the region. In the end, the actual deficit was significantly lower than forecast, closing at just £49,008. This positive variance was largely due to stronger-than-expected income from the Singapore meeting, both in terms of sponsorship and delegate registrations, as well as higher-than-budgeted revenue from the Society's journal. The outcome reflects prudent financial management and the success of the Society's efforts to broaden its international engagement.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation and remain optimistic that continued development of activities and worldwide promotion of the Society will assure a long-term future for the Society.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

Reserves Policy

The reserves policy that was reviewed in 2023 to ensure compliance with current Charity Commission guidance remains in place. The annual teaching course is the Society's flagship event and primary income stream, representing significant financial undertaking for the Society. The Trustees remain committed to holding reserves sufficient to cover all potential costs in the event of a failed or aborted annual teaching course. Additional requirement for reserves identified in this period included unforeseen costs associated with replacement of the Society website/administrative system, an investment required to ensure future stability. Furthermore, the continued decline in industry support due to worldwide economic factors could necessitate use of reserves to maintain Society functions with potential increase in staff costs if additional cover were needed to support the small team.

The Society had unrestricted reserves of £347,016 that were not invested in fixed assets at the year end to February 2025; (2024: £395,911).

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees work to improve and expand the educational portfolio of the Society, to reach colleagues in the radiology community internationally and generate financial stability to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components of this strategy, in addition to attracting industry support, generating sufficient income to sustain the administrative structure and maintain reserves.

The Executive Board continues to believe that a combination of in-person and online courses provides the best balance of educational activity, and this balance will be maintained when programming future events, taking into account continued global economic pressures.

The 24th ICIS Annual Teaching Course will take place from 24–26 September 2025 at the Hague Conference Centre, The Netherlands. With Professor Thierry Huisman serving as Meeting President, the event marks a return to Europe following the Society's first Asian-based conference in 2024. The 2025 meeting is themed "Precision Diagnostics: Advancing Oncological Imaging Breakthroughs" and will bring together a distinguished international faculty of ICIS Fellows and global experts to deliver a comprehensive, multidisciplinary programme. The course will focus on the evolving role of precision imaging and image-guided interventions in oncology, with particular emphasis on imaging biomarkers, AI-driven diagnostics, and integrated clinical-radiological practice.

Following an invitation from Siemens Healthineers, the ICIS Interactive Masterclass on Gynaecological Cancers was conducted at their Academy facility in Warsaw, Poland, in May 2024. This was well received. Faculty and venue availability meant no further courses were scheduled there for the rest of the financial year, however, the ICIS Interactive Masterclass on Prostate Cancer is being planned for that venue in 2026. The ever-popular Masterclass in Whole-Body MRI was held online in July 2024; and a second course was run in-person in a venue in central Stockholm in November 2024. In 2025 Masterclasses in Rectal and Head & Neck Cancers will be delivered online and plans are well underway for a full programme in 2026.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

The 'Read with the Experts' series originally launched in February 2023 focusing on hepatobiliary imaging would be re-run in the second half of 2025 as part of a collaboration with the Sao Paulo Radiology Society (SPR). A total of six segments would be delivered, five curated by ICIS Fellows and the sixth by a senior SPR member. The CMRAD platform would be utilised.

A further ICIS in Focus meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging was put on hold in 2025 due to staff capacity amid changes of personnel and the project to update the website and administration system. It is being considered for 2026, most likely as a partnership with Forth University in Heraklion, Crete. Ring-fenced funds following the 2023 ICIS in Focus course are available to support this initiative.

The Trustees have agreed that the 2026 annual teaching course will return to the United Kingdom following the usual pattern of being held in the UK every three years. The preferred location has been confirmed as Belfast, Northern Ireland which will represent the first annual teaching course to be held in Northern Ireland.

The series of bi-monthly webinars covering a variety of topics, planned by the e-learning committee, will continue as these generate substantial audiences with a wide geographical spread. Collaborations with other societies are considered to broaden the reach and establish relationships for future joint ventures.

A collaboration under the guidance of a Memorandum of Understanding with the Radiological Society of Sao Paulo (SPR) was finalised in September 2024 and was followed by a joint webinar in November 2024. Regular joint scientific sessions as part of the respective annual teaching course are planned for both the Jornada Paulista de Radiologia in Sao Paulo in May 2025 and the ICIS annual course in The Hague in September 2025.

A similar collaboration with the Indian Radiological and Imaging Association (IRIA) was finalised in March 2025 following a joint scientific session at the Asian and Oceanic Congress of Radiology held jointly with IRIA in Chennai, India in January 2025.

Other international partners may be explored to expand the Society's worldwide reach.

Opportunities to establish further satellite meetings from 2025 are being explored with the first planned to be held in Oman in January 2026. These meetings present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows.

An appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society, and Fellows representing the Society are not exposed to any personal risk. The Society does not cover any speaker expenses; these costs must be met by the host societies or personally.

Marketing Society activities and 'Cancer Imaging' will remain a priority; electronic means and social media enable enhanced communication with members and the wider international community with an interest in oncological imaging. The benefits of membership will be reviewed and assessment of options presented by online education to assist in promoting the Society and enhancing the appeal of membership. Google analytics of traffic to the ICIS website permits review of activity and the number of members will continue to be monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion. With the introduction of the new IT system, website analytics will be enhanced to inform on current activity and future developments.

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

A review of the overall Society strategy had been planned for late 2024 / 2025 to establish that Society activities and plans are relevant for the current requirements and expectations of the international radiological community and those embarking on a career in this specialist field. Due to changes in personnel and the website/administration system project, this was put on hold and will now be undertaken in late 2025/2026.

By order of the Board on 23 September 2025



Trevor Pereira
Secretary

**INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28th February 2025 set out on pages 12 to 19.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Paul Newton FCA
JCS Accountants Ltd
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date:

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account) FOR THE YEAR ENDED 28TH FEBRUARY 2025

		2025			2024		
		Unrestricted Funds	Restricted Funds	Total	Unrestricted Funds	Restricted Funds	Total
	Note	£	£	£	£	£	£
Income from:							
Charitable activities							
Conference sponsorship and funding		54,280	-	54,280	118,340	29,782	148,122
Revenue from conference delegates		-	-	-	146,938	-	146,938
Membership income		20,752	-	20,752	15,577	-	15,577
ICIS Interactives		51,679	-	51,679	30,504	-	30,504
Journal income		51,684	-	51,684	32,895	-	32,895
Interest receivable		<u>7,836</u>	<u>-</u>	<u>7,836</u>	<u>4,763</u>	<u>-</u>	<u>4,763</u>
Total income		<u>186,231</u>	<u>-</u>	<u>186,231</u>	<u>349,017</u>	<u>29,782</u>	<u>378,799</u>
Expenditure on:							
Charitable activities	2	<u>235,239</u>	<u>-</u>	<u>235,239</u>	<u>272,066</u>	<u>16,712</u>	<u>288,778</u>
Total expenditure		<u>235,239</u>	<u>-</u>	<u>235,239</u>	<u>272,066</u>	<u>16,712</u>	<u>288,778</u>
Net income/(expenditure) and movement in funds		<u>(49,008)</u>	<u>-</u>	<u>(49,008)</u>	76,951	13,070	90,021
Reconciliation of funds							
Total funds brought forward		<u>396,365</u>	<u>13,070</u>	<u>409,435</u>	<u>319,414</u>	<u>-</u>	<u>319,414</u>
Total funds carried forward		<u>347,357</u>	<u>13,070</u>	<u>360,427</u>	<u>396,365</u>	<u>13,070</u>	<u>409,435</u>

The notes on pages 14 to 19 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET AS AT 28TH FEBRUARY 2025


		2025		2024	
	Note	£	£	£	£
Fixed assets					
Tangible fixed assets	3		341		454
Current assets					
Debtors	4	85,444		41,871	
Cash at bank and in hand		<u>298,366</u>		<u>393,118</u>	
		383,810		434,989	
Creditors: Amounts falling due within one year	5	<u>23,724</u>		<u>26,008</u>	
Net current assets			360,086		408,981
Total Net assets less current liabilities			360,427		409,435
Funds					
Unrestricted funds	6		347,357		396,365
Restricted funds	7		<u>13,070</u>		<u>13,070</u>
Total Funds	8		360,427		409,435


These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2025 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 23 September 2025 and signed on their behalf by:


Dr. Aslam Sohaib
Trustee


Prof. Dow Mu Koh
Trustee

Registered Charity No: 1082082

Company Registration No: 03908709

The notes on pages 14 to 19 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2025

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

2 EXPENDITURE ON CHARITABLE ACTIVITIES

	Unrestricted Funds £	Restricted Funds £	Total 2025 £	Unrestricted Funds £	Restricted Funds £	Total 2024 £
Expenditure on Charitable activities						
Conference costs	16,560	-	16,560	85,916	9,950	95,866
Design, production and advertising	3,540	-	3,540	6,094	150	6,244
Administration						
- Staff costs (see note 9)	91,174	-	91,174	71,195	2,031	73,226
- Secretarial Services	10,314	-	10,314	6,665	1,700	8,365
- Other	-	-	-	2,500	-	2,500
Pension Scheme	310	-	310	284	-	284
Travel and accommodation	24,189	-	24,189	7,083	2,655	9,738
Printing	1,863	-	1,863	4,473	226	4,699
Bank charges and credit card charges	1,294	-	1,294	3,999	-	3,999
Insurance	872	-	872	654	-	654
Gifts and donations	94	-	94	1,185	-	1,185
Accreditations	892	-	892	353	-	353
Utilities	161	-	161	171	-	171
Postage/delivery charges	2,322	-	2,322	2,472	-	2,472
Telephone	488	-	488	525	-	525
Depreciation	114	-	114	152	-	152
Software expenses	3,874	-	3,874	1,119	-	1,119
IT support	17,317	-	17,317	27,885	-	27,885
Miscellaneous	8	-	8	-	-	-
Rent	1,030	-	1,030	1,020	-	1,020
Licenses and Permits	8,253	-	8,253	7,544	-	7,544
Accounting	41,106	-	41,106	39,889	-	39,889
Professional Fees	1,224	-	1,224	504	-	504
Independent Examiners fees	2,316	-	2,316	2,205	-	2,205
Foreign exchange losses/(gains)	5,924	-	5,924	(1,821)	-	(1,821)
	<u>235,239</u>	<u>-</u>	<u>235,239</u>	<u>272,066</u>	<u>16,712</u>	<u>288,778</u>

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

3 TANGIBLE FIXED ASSETS

	Computer Equipment £	Total £
Cost		
As at 1st March 2024	1,150	1,150
Additions	-	-
Disposals	-	-
As at 28th February 2025	<u>1,150</u>	<u>1,150</u>
Depreciation		
As at 1st March 2024	695	695
Charge for year	114	114
Disposals	-	-
As at 28th February 2025	<u>809</u>	<u>809</u>
Net book value		
As at 28th February 2025	<u>341</u>	<u>341</u>
As at 29th February 2024	<u>454</u>	<u>454</u>

4 DEBTORS

	2025 £	2024 £
Trade debtors	12,430	8,975
Prepayments and accrued income	<u>73,014</u>	<u>32,896</u>
	<u>85,444</u>	<u>41,871</u>

5 CREDITORS

	2025 £	2024 £
Trade creditors	3,801	2,021
Accruals and deferred income	<u>19,923</u>	<u>23,987</u>
	<u>23,724</u>	<u>26,008</u>
Deferred income is included within:		
Current liabilities	<u>3,455</u>	-
Movement in the year:		
Deferred income at 1 st March 2024	-	6,364
Released from previous periods	-	(6,364)
Resources deferred in the year	<u>3,455</u>	-
Deferred income at 28th February 2025	<u>3,455</u>	-

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

6 UNRESTRICTED FUNDS

	At 1st March 2024 £	Total Income £	Total Expenditure £	At 28th February 2025 £
Unrestricted Funds				
General Fund	<u>396,365</u>	<u>186,231</u>	<u>(235,239)</u>	<u>347,357</u>

	At 1st March 2023 £	Total Income £	Total Expenditure £	At 28th February 2024 £
Unrestricted Funds				
General Fund	<u>319,414</u>	<u>349,017</u>	<u>(272,066)</u>	<u>396,365</u>

7 RESTRICTED FUNDS

	At 1st March 2024 £	Total Income £	Total Expenditure £	At 28th February 2025 £
Restricted Funds				
AI Meeting	<u>13,070</u>	<u>-</u>	<u>-</u>	<u>13,070</u>

	At 1st March 2023 £	Total Income £	Total Expenditure £	At 29th February 2024 £
Restricted Funds				
AI Meeting	<u>-</u>	<u>29,782</u>	<u>(16,712)</u>	<u>13,070</u>

AI Meeting

This relates to funds received for the AI Meetings that started in 2023.

8 ANALYSIS OF NET ASSETS BY FUND

2025	Unrestricted £	Restricted £	Total £
Tangible fixed assets	341	-	341
Net current assets	<u>347,016</u>	<u>13,070</u>	<u>360,086</u>
	<u>347,357</u>	<u>13,070</u>	<u>360,427</u>
2024	Unrestricted £	Restricted £	Total £
Tangible fixed assets	454	-	454
Net current assets	<u>395,911</u>	<u>13,070</u>	<u>408,981</u>
	<u>396,365</u>	<u>13,070</u>	<u>409,435</u>

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2025 (continued)

9 STAFF COSTS

	2025 £	2024 £
Salaries	85,860	69,444
Pension	2,010	1,709
Social security	<u>3,304</u>	<u>2,073</u>
	<u>91,174</u>	<u>73,226</u>
Average no. staff	<u>3</u>	<u>2</u>

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £47,904 (2024: £47,355). There were no other related party transactions in the year.

10 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2024: none). Travel expenses incurred on behalf of the Society and reimbursed during the year to 28th February 2025 related to one trustee and amounted to £nil (2024: £1,500).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

11 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.